STAT+: What’s next for Cassava Sciences, and Cartesian Therapeutics has a novel excuse for dodgy data
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Taking time off is nice, but returning for a July 4-shortened workweek is a bit discombobulating. Speaking of which, I’m landing in your inbox a day early because of the holiday. I hope you eat many hot dogs and watch amazing fireworks. Happy Birthday, America!
Let’s recap a wild week for Cassava Sciences
On Friday, the Justice Department charged the company’s chief scientific collaborator and paid consultant, Hoau-Yan Wang, with multiple counts of fraud. According to the indictment, Wang, a professor at City University of New York, fabricated and falsified data pertaining to Cassava’s drug for Alzheimer’s disease, called simufilam, in order to obtain $16 million in grants from the National Institutes of Health for himself and Cassava.
